Cargando…
Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
BACKGROUND AND OBJECTIVES: Immune-checitors have been established as a novel standard treatment for non-small cell lung cancer (NSCLC). The aim of this study was to identify factors associated with efficacy and nivolumab-related interstitial pneumonia in NSCLC by evaluating clinical data at the init...
Autores principales: | Hata, Hiroki, Mio, Tadashi, Yamashita, Daisuke, Matsumura, Chikako, Chisaki, Yugo, Motohashi, Hideyuki, Yano, Yoshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480353/ https://www.ncbi.nlm.nih.gov/pubmed/33297768 http://dx.doi.org/10.1177/1073274820977200 |
Ejemplares similares
-
A Retrospective Cohort Study of Multiple Immune-Related Adverse
Events and Clinical Outcomes Among Patients With Cancer Receiving Immune
Checkpoint Inhibitors
por: Hata, Hiroki, et al.
Publicado: (2022) -
Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017) -
Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
por: Kanai, Osamu, et al.
Publicado: (2018) -
Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
por: Imakita, Takuma, et al.
Publicado: (2017) -
Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)